Reemplazo endovascular aórtico en un paciente con enfermedad de válvula aórtica bicúspide / Endovascular aortic replacement in a patient with bicuspid aortic valve disease

Resumen Un varón de 49 años ingresó en la unidad de cuidados coronarios, con antecedentes de miocardiopatía dilatada, con función sistólica del ventrículo izquierdo gravemente deteriorada y estenosis aórtica grave de origen bicúspide, sintomático para síncope, ángor y disnea de reciente diagnóstico. Durante la internación evolucionó con shock cardiogénico que requirió doble soporte inotrópico. Por presentar alto riesgo quirúrgico y elevada probabilidad de rechazo ante un eventual trasplante cardiaco, según sus estudios de histocompatibilidad, se procedió al reemplazo transcatéter de la válvula aortica, con evolución favorable.

Abstract A 49-year-old male with a history of left ventricular systolic function dilated cardiomyopathy and severe symptomatic bicuspid aortic stenosis recently diagnosed (syncope, chest pain and dyspnea) was admitted to the coronary care unit. During hospitalization, he developed cardiogenic shock requiring double inotropic support. High surgical risk and an elevated chance of graft rejection contraindicated surgical replacement or heart transplant. We performed a transcatheter aortic valve replacement with a favorable evolution.

[Endovascular aortic replacement in a patient with bicuspid aortic valve disease]. / Reemplazo endovascular aórtico en un paciente con enfermedad de válvula aórtica bicúspide.

A 49-year-old male with a history of left ventricular systolic function dilated cardiomyopathy and severe symptomatic bicuspid aortic stenosis recently diagnosed (syncope, chest pain and dyspnea) was admitted to the coronary care unit. During hospitalization, he developed cardiogenic shock requiring double inotropic support. High surgical risk and an elevated chance of graft rejection contraindicated surgical replacement or heart transplant. We performed a transcatheter aortic valve replacement with a favorable evolution.

Un varón de 49 años ingresó en la unidad de cuidados coronarios, con antecedentes de miocardiopatía dilatada, con función sistólica del ventrículo izquierdo gravemente deteriorada y estenosis aórtica grave de origen bicúspide, sintomático para síncope, ángor y disnea de reciente diagnóstico. Durante la internación evolucionó con shock cardiogénico que requirió doble soporte inotrópico. Por presentar alto riesgo quirúrgico y elevada probabilidad de rechazo ante un eventual trasplante cardiaco, según sus estudios de histocompatibilidad, se procedió al reemplazo transcatéter de la válvula aortica, con evolución favorable.

[In-hospital complications of acute myocardial infarction. Incidence and timing of their occurrence]. / Complicaciones intrahospitalarias del infarto agudo de miocardio. Incidencia y momento de aparición.

Although ST-segment elevation myocardial infarction (STEMI) mortality decreased with the progress of reperfusion, the incidence of hospital complications has not changed. We aimed to describe the incidence of STEMI complications in the coronary unit, the timing of their occurrence and to identify their predisposing and protective factors. This is a prospective analysis of all consecutive patients with STEMI admitted to a coronary care unit of a third level reference hospital from September 2017 to March 2020. Of the 263 STEMI, 124 developed complications (47.2%), and the most frequent was heart failure. In the multivariate analysis, preadmission cardiac arrest (CA) (OR: 9.8; CI: 1.2-81.9; p = 0.03), left ventricular ejection fraction (Fey VI) < 40% (OR: 2.3 CI: 1.3-3.9; p = 0.004) and age > 68 years (OR: 2.2; CI: 1.2-4.0; p = 0.01) were predictors of complications. Successful reperfusion (OR: 0.2 CI: 0.005-0.7; p = 0.02) and the presentation of Killip and Kimball (KK) A (OR: 0.0002 CI: 0.00001-0.003; p = < 0.00001) were protective factors. Most complications occurred on the first day (88.7%) and in all but one patient within the first 48 hours. Acute complications of STEMI occurred very frequently and the most prevalent was heart failure. KKA and successful reperfusion are low risks predictors, while 6 out of 10 patients with Fey VI < 40%, Cardiac arrest before admission or age >68 years suffered an event. Almost all complications happened within the first 48 hours.

Aunque la mortalidad del infarto de miocardio con elevación del segmento ST (IAMCEST) ha disminuido con el progreso de la reperfusión, la incidencia de sus complicaciones no ha cambiado. El objetivo del estudio es conocer la incidencia de las complicaciones hospitalarias del IAMCEST, su cronología de aparición e identificar sus predictores. Se realizó un análisis prospectivo de todos los pacientes consecutivos con IAMCEST ingresados en una unidad coronaria de un Hospital público de la ciudad de Buenos Aires desde septiembre de 2017 a marzo de 2020. De 263 pacientes con IAMCEST, el 47.2% (124) presentó complicaciones siendo la insuficiencia cardíaca (IC) la más frecuente. El paro cardiaco previo al ingreso (PCR) (OR: 9.8; IC: 1.2-81.9; p = 0.03), la fracción de eyección del ventrículo izquierdo (Fey VI) < del 40% (OR: 2.3 IC: 1.3-3.9; p = 0.004) y la edad > de 68 años (OR: 2.2; IC: 1.2-4,0; p = 0.01) fueron sus predictores. La reperfusión exitosa (OR: 0.2 IC: 0.005-0.7; p = 0.02) y la presentación de Killip y Kimball (KK) A (OR: 0.0002 IC: 0.00001-0.003; p = < 0.00001) fueron factores protectores. El 88.7% (110) se complicó el primer día de internación y todos (con excepción de un solo paciente) dentro de las 48 horas. Las complicaciones post IAMCEST son muy frecuentes, suceden dentro de los primeros dos días de internación y la IC es la más prevalente. Detectamos un grupo con menor riesgo que podría tener una internación abreviada de solo 48 horas.

Complicaciones intrahospitalarias del infarto agudo de miocardio. Incidencia y momento de aparición / In-hospital complications of acute myocardial infarction. Incidence and timing of their occurrence

Resumen Aunque la mortalidad del infarto de miocardio con elevación del segmento ST (IAMCEST) ha disminuido con el progreso de la reperfusión, la incidencia de sus complicaciones no ha cambiado. El objetivo del estudio es conocer la incidencia de las complicaciones hospitalarias del IAMCEST, su cronología de aparición e identificar sus predictores. Se realizó un análisis prospectivo de todos los pacientes consecutivos con IAMCEST ingresados en una unidad coronaria de un Hospital público de la ciudad de Buenos Aires desde septiembre de 2017 a marzo de 2020. De 263 pacientes con IAMCEST, el 47.2% (124) presentó complicacio nes siendo la insuficiencia cardíaca (IC) la más frecuente. El paro cardiaco previo al ingreso (PCR) (OR: 9.8; IC: 1.2-81.9; p = 0.03), la fracción de eyección del ventrículo izquierdo (Fey VI) < del 40% (OR: 2.3 IC: 1.3-3.9; p = 0.004) y la edad > de 68 años (OR: 2.2; IC: 1.2-4,0; p = 0.01) fueron sus predictores. La reperfusión exitosa (OR: 0.2 IC: 0.005-0.7; p = 0.02) y la presentación de Killip y Kimball (KK) A (OR: 0.0002 IC: 0.00001-0.003; p = < 0.00001) fueron factores protectores. El 88.7% (110) se complicó el primer día de internación y todos (con excepción de un solo paciente) dentro de las 48 horas. Las complicaciones post IAMCEST son muy frecuentes, suceden dentro de los primeros dos días de internación y la IC es la más prevalente. Detectamos un grupo con menor riesgo que podría tener una internación abreviada de solo 48 horas.

Abstract Although ST-segment elevation myocardial infarction (STEMI) mortality decreased with the progress of reperfusion, the incidence of hospital complications has not changed. We aimed to describe the incidence of STEMI complications in the coronary unit, the timing of their occurrence and to identify their predis posing and protective factors. This is a prospective analysis of all consecutive patients with STEMI admitted to a coronary care unit of a third level reference hospital from September 2017 to March 2020. Of the 263 STEMI, 124 developed complications (47.2%), and the most frequent was heart failure. In the multivariate analysis, pre-admission cardiac arrest (CA) (OR: 9.8; CI: 1.2-81.9; p = 0.03), left ventricular ejection fraction (Fey VI) < 40% (OR: 2.3 CI: 1.3-3.9; p = 0.004) and age > 68 years (OR: 2.2; CI: 1.2-4.0; p = 0.01) were predictors of complica tions. Successful reperfusion (OR: 0.2 CI: 0.005-0.7; p = 0.02) and the presentation of Killip and Kimball (KK) A (OR: 0.0002 CI: 0.00001-0.003; p = < 0.00001) were protective factors. Most complications occurred on the first day (88.7%) and in all but one patient within the first 48 hours. Acute complications of STEMI occurred very frequently and the most prevalent was heart failure. KKA and successful reperfusion are low risks predictors, while 6 out of 10 patients with Fey VI < 40%, Cardiac arrest before admission or age >68 years suffered an event. Almost all complications happened within the first 48 hours.

Detección de barreras e implementación de procedimientos para reducir la demora en el tratamiento del síndrome coronario agudo con elevación del segmento ST mediante angioplastia primaria / Barriers and Procedures to Reduce Treatment Delay in ST-Segment Elevation Acute Coronary Syndrome with Primary Percutaneous Coronary Intervention

RESUMEN Introducción: La demora a la reperfusión del síndrome coronario agudo con elevación del segmento ST es un factor determinante en el pronóstico. Su reducción podría disminuir la morbimortalidad. Objetivo: Identificar y modificar las barreras detectadas en 20 años de tratamiento del síndrome coronario agudo con elevación del segmento ST en un centro de tercer nivel de una ciudad de alta densidad demográfica para evaluar su efecto en el resultado del procedimiento. Material y métodos: Incluimos prospectiva y consecutivamente del 01/01/2000 al 31/12/2019, 3007 pacientes con síndrome coronario agudo con elevación del segmento ST dentro de las 12 h de iniciados los síntomas para realizar angioplastia primaria. Se dividió el tiempo desde el comienzo de los síntomas hasta la insuflación del balón en intervalos. Luego de identificar las barreras (2000-2009) se incorporaron cambios al procedimiento. Se organizó a la población en 2 grupos (G) G1: preimplementación de cambios (2000-2009) y G2: posimplementación (2010- 2019). Resultados: Se incluyeron en G1 1409 pacientes y en G2 1598. Sin diferencias demográficas, excepto por el tipo de angioplastia. Se identificaron demoras al realizar el diagnóstico, de comunicación entre médicos, del traslado y del ingreso del paciente a hemodinamia. Con los cambios, disminuimos el intervalo consulta-contacto con el hemodinamista [G1: 90 min (36-168) vs. G2: 77 min (36-144) p -0,01] y el intervalo contacto hemodinamista-ingreso a Hemodinamia [G1: 75 min (55-100) vs. G2: 51 min (34-70) p -0,01]. Se redujo la mortalidad intrahospitalaria (G1: 9,2% vs. G2:6,7% p -0,01) y al 6to mes (G1: 13,1% vs. G2: 7,5% p -0,01). Conclusiones: El retraso al diagnóstico, la dificultad en la comunicación y la forma de traslado fueron las principales causas de demora. La implementación de un protocolo de procedimientos permitió reducir las demoras. La evaluación continua de resultados y la educación permanente, constituyen los pilares fundamentales para la optimización de programas de atención en red.

ABSTRACT Background: The delay to reperfusion of ST-segment elevation acute coronary syndrome (STEACS) is a key factor in its prognosis, and its reduction could reduce morbidity and mortality. Objective: The aim of this study was to identify and modify the barriers detected in 20 years of STEACS treatment in a tertiary care center of a densely populated city to evaluate their effect on the outcome of the procedure. Methods: A total of 3007 patients with STEACS within 12 hours of symptoms onset were prospectively and consecutively included to undergo primary percutaneous coronary intervention (PCI) from January 1, 2000 to December 31, 2019. Time from symptoms onset to balloon inflation was divided into intervals. After barriers were identified (2000-2009), the procedure was changed. The population was divided into two groups (G) G1: pre-implementation (2000-2009) and G2: post-implementation (2010-2019) of changes. Results: G1 included 1409 and G2 1598 patients with no demographic differences except for the type of PCI. Delays were identified in diagnosis, communication between physicians, transfer and admission of the patient to the hemodynamics lab. Procedural changes decreased first medical contact-hemodynamic team contact interval [G1: 90 min (36-168) vs. G2: 77 min (36-144) p -0.01] and hemodynamic team contact-hemodynamics lab admission interval [G1: 75 min (55-100) vs. G2: 51 min (34-70) p -0.01] and reduced in-hospital (G1: 9,2% vs. G2: 6,7% p -0,01) and 6-month (G1: 13.1% vs. G2: 7.5% p -0. 01) mortality. Conclusions: Delay in diagnosis, difficulty in communication and type of transfer were the most important causes of delay. Implementing a procedural protocol reduced delays. Continuous evaluation of results and permanent education constitute the fundamental cornerstones for optimizing network care programs.

Impact of a prolonged COVID-19 lockdown on patterns of admission, mortality and performance indicators in a cardiovascular intensive care unit.

BACKGROUND: The effects of an early and prolonged lockdown during the coronavirus disease 2019 (COVID-19) pandemic on cardiovascular intensive care units (CICUs) are not well established. OBJECTIVES: This study analyses patterns of admission, mortality and performance indicators in a CICU before and during the Argentine lockdown in the COVID-19 pandemic. METHODS: This is a retrospective observational cross-sectional study of all consecutive patients aged 18 years or more admitted to the cardiac intensive care unit at a high-volume reference hospital in Buenos Aires, Argentina, comparing hospitalization rates, primary causes of admission, inpatient utilization indicators, pharmacy supplies' expenditures and in-hospital mortality between 5 March and 31 July 2020, with two corresponding control periods in 2019 and 2018. RESULTS: We included 722 female patients [mean age of 61.6 (SD 15.5) years; 237 (32.8%)]. Overall hospitalizations dropped 53.2% (95%CI: 45.3, 61.0%), from 295.5 patients/year over the periods 2018/2019 to 137 patients in 2020. Cardiovascular disease-related admissions dropped 59.9%, while admission for non-cardiac causes doubled its prevalence from 9.6% over the periods 2018/2019 to 22.6% in the study period (P < 0.001).In the period 2020, the bed occupancy rate fell from 82.2% to 77.4%, and the bed turnover rate dropped 50% from 7.88 to 3.91 monthly discharges/bed. The average length of stay doubled from 3.26 to 6.75 days, and the turnover interval increased from 3.8 to 8.39 days in 2020.Pharmacy supplies' expenditures per discharge increased 134% along with a rise in antibiotics usage from 6.5 to 11.4 vials/ampoules per discharge (P < 0.02).Overall mortality increased from 7% (n = 41) to 13.9% (n = 19) (P = 0.008) at the expense of non-cardiac-related admissions (3.6-19.4%, P = 0.01). CONCLUSIONS: This study found a significant reduction in overall and cardiovascular disease-related causes of admission to the cardiac intensive care unit, worse performance indicators and increased in-hospital mortality along the first 5 months of the early and long-lasting COVID-19 lockdown in Argentina. These results highlight the need to foster public awareness concerning the risks of avoiding hospital attendance. Moreover, health systems should follow strict screening protocols to prevent potential biases in the admission of patients with critical conditions unrelated to the COVID-19 pandemic.

[Cilostazol and sick sinus syndrome]. / Efecto del cilostazol en la enfermedad del nodo sinusal.

Here we present the case of a 60-year-old patient with sinus node disease (NSS), symptomatic with dizziness and angor. The electrocardiogram showed episodes of sinus pauses with nodal escapes. During hospitalization, pending the placement of a definitive pacemaker, cilostazol (100 mg every 12 hours orally) was indicated, observing an increase in heart rate 48 hours after starting the medication, and the disappearance of sinus pauses in the 24 hours Holter. Our objective has been to show that cilostazol can be useful in patients with SNN, although long-term chronotropic effects of this treatment has yet to be evaluated.

Se presenta el caso de una paciente de 60 años con enfermedad del nodo sinusal (ENS), sintomática con mareos y ángor, con electrocardiograma que evidenciaba episodios de pausas sinusales con escapes nodales. Durante la internación, a la espera de colocación de marcapaso definitivo, se indicó cilostazol (100 mg cada 12 h vía oral), observando a las 48 horas del inicio un incremento en la frecuencia cardíaca y la desaparición de las pausas sinusales en Holter de 24 horas. Nue stro objetivo ha sido demostrar que el cilostazol puede ser útil en pacientes con ENS, aunque es necesario evaluar los efectos cronotrópicos a largo plazo de este tratamiento.

Efecto del cilostazol en la enfermedad del nodo sinusal / Cilostazol and sick sinus syndrome

Resumen Se presenta el caso de una paciente de 60 años con enfermedad del nodo sinusal (ENS), sintomática con mareos y ángor, con electrocardiograma que evidenciaba episodios de pausas sinusales con escapes nodales. Durante la internación, a la espera de colocación de marcapaso definitivo, se indicó cilostazol (100 mg cada 12 h vía oral), observando a las 48 horas del inicio un incremento en la frecuencia cardíaca y la desaparición de las pausas sinusales en Holter de 24 horas. Nuestro objetivo ha sido demostrar que el cilostazol puede ser útil en pacientes con ENS, aunque es necesario evaluar los efectos cronotrópicos a largo plazo de este tratamiento.

Abstract Here we present the case of a 60-year-old patient with sinus node disease (NSS), symptomatic with dizziness and angor. The electrocardiogram showed episodes of sinus pauses with nodal escapes. During hospitalization, pending the placement of a definitive pacemaker, cilostazol (100 mg every 12 hours orally) was indicated, observing an increase in heart rate 48 hours after starting the medication, and the disappearance of sinus pauses in the 24 hours Holter. Our objective has been to show that cilostazol can be useful in patients with SNN, although long-term chronotropic effects of this treatment has yet to be evaluated.

[Pulmonary embolism. Clinical suspicion and anatomopathological correlation]. / Tromboembolismo de pulmón. Sospecha clínica y correlación anatomopatológica.

Discrepancies between clinical suspicion and pathological findings in pulmonary embolism (PE) appear to be frequent. The aim of this study was to analyze the prevalence of PE in a necropsy series of patients who have died in an acute care hospital between 1998-2017, its relationship with previous clinical suspicion, and its importance as a cause of death. It is a retrospective observational study of 350 autopsies done at the Department of Pathology. We analyzed the demographic characteristics, main clinical diagnoses stated in the autopsy request form, incidence of PE diagnosed, main autopsy findings related with the cause of death, as well as the concordance between clinical suspicion and autopsy diagnosis. In only 8% of the cases (n = 28) the clinical diagnosis of autopsy request was PE. An autopsy diagnosis of PE was done in 127 cases (36.3%); in 33 cases (25.9%) affected large pulmonary vessels; medium caliber vessels were affected in 75 cases (59.1%), and in 19 cases small vessels. The PE was considered as a contributor or cause of death in 30.9% (n = 108). However, only 15.7% of the confirmed PE cases had previous clinical suspicion. This series of necropsies shows that PE is a high prevalence finding in autopsies at an acute care hospital, and an important cause of death in a 20 years period. The finding of a low concordance with clinical diagnosis should alert the medical community on the importance of clinical suspicion in order to achieve an early diagnosis and treatment of this disease.

Las discrepancias entre la sospecha clínica y los hallazgos patológicos en el tromboembolismo pulmonar (TEP) son frecuentes. El objetivo de este estudio fue analizar la prevalencia de TEP en una serie de necropsias de fallecidos en un hospital general de agudos entre 1998 y 2017, su relación con la sospecha clínica y su importancia como causa de muerte. Es un estudio retrospectivo y observacional de 350 autopsias realizadas en el Servicio de Patología; analiza características demográficas, principales diagnósticos clínicos informados en la solicitud de autopsia (sospecha clínica de muerte), incidencia anatomopatológica de TEP, diagnósticos primarios de autopsia relacionados con la muerte y concordancia entre sospecha clínica y diagnósticos de autopsia. En solo el 8% de las autopsias (n = 28), el TEP fue el diagnóstico clínico informado. En las autopsias, se encontró TEP en 127 casos (36.3%). Afectó arterias pulmonares grandes en 33 casos (25.9%), vasos medianos en 75 (59.1%) y vasos pequeños en 19 casos. El TEP se consideró el principal contribuyente o la causa principal de muerte en un 30.9% (n = 108) de los casos. Sin embargo, solo en el 15.7% de los casos confirmados había una sospecha clínica previa de TEP. Esta serie muestra que el TEP es un hallazgo de alta prevalencia y una causa importante de muerte en autopsias realizadas en un hospital de agudos. La evidencia de la baja concordancia entre los diagnósticos anatomopatológicos y clínicos del TEP alerta sobre la importancia de la sospecha clínica para lograr un tratamiento temprano de la enfermedad.

Tromboembolismo de pulmón: Sospecha clínica y correlación anatomopatológica / Pulmonary embolism. Clinical suspicion and anatomopathological correlation

Las discrepancias entre la sospecha clínica y los hallazgos patológicos en el tromboembolismo pulmonar (TEP) son frecuentes. El objetivo de este estudio fue analizar la prevalencia de TEP en una serie de necropsias de fallecidos en un hospital general de agudos entre 1998 y 2017, su relación con la sospecha clínica y su importancia como causa de muerte. Es un estudio retrospectivo y observacional de 350 autopsias realizadas en el Servicio de Patología; analiza características demográficas, principales diagnósticos clínicos informados en la solicitud de autopsia (sospecha clínica de muerte), incidencia anatomopatológica de TEP, diagnósticos primarios de autopsia relacionados con la muerte y concordancia entre sospecha clínica y diagnósticos de autopsia. En solo el 8% de las autopsias (n = 28), el TEP fue el diagnóstico clínico informado. En las autopsias, se encontró TEP en 127 casos (36.3%). Afectó arterias pulmonares grandes en 33 casos (25.9%), vasos medianos en 75 (59.1%) y vasos pequeños en 19 casos. El TEP se consideró el principal contribuyente o la causa principal de muerte en un 30.9% (n = 108) de los casos. Sin embargo, solo en el 15.7% de los casos confirmados había una sospecha clínica previa de TEP. Esta serie muestra que el TEP es un hallazgo de alta prevalencia y una causa importante de muerte en autopsias realizadas en un hospital de agudos. La evidencia de la baja concordancia entre los diagnósticos anatomopatológicos y clínicos del TEP alerta sobre la importancia de la sospecha clínica para lograr un tratamiento temprano de la enfermedad.

Discrepancies between clinical suspicion and pathological findings in pulmonary embolism (PE) appear to be frequent. The aim of this study was to analyze the prevalence of PE in a necropsy series of patients who have died in an acute care hospital between 1998-2017, its relationship with previous clinical suspicion, and its importance as a cause of death. It is a retrospective observational study of 350 autopsies done at the Department of Pathology. We analyzed the demographic characteristics, main clinical diagnoses stated in the autopsy request form, incidence of PE diagnosed, main autopsy findings related with the cause of death, as well as the concordance between clinical suspicion and autopsy diagnosis. In only 8% of the cases (n = 28) the clinical diagnosis of autopsy request was PE. An autopsy diagnosis of PE was done in 127 cases (36.3%); in 33 cases (25.9%) affected large pulmonary vessels; medium caliber vessels were affected in 75 cases (59.1%), and in 19 cases small vessels. The PE was considered as a contributor or cause of death in 30.9% (n = 108). However, only 15.7% of the confirmed PE cases had previous clinical suspicion. This series of necropsies shows that PE is a high prevalence finding in autopsies at an acute care hospital, and an important cause of death in a 20 years period. The finding of a low concordance with clinical diagnosis should alert the medical community on the importance of clinical suspicion in order to achieve an early diagnosis and treatment of this disease.

Is Dual-Axis Rotational Coronary Angiography Radiation Dose Reduction Achievable in a Population with 100% Suspected Coronary Artery Disease? A Randomized Trial.

BACKGROUND: Previous studies have shown a reduction in radiation dose and contrast volume using dual-axis rotational coronary angiography (DARCA), but this has not been replicated in a population with 100% coronary artery disease (CAD). OBJECTIVE: To find if DARCA dose reduction is achievable in this population, we sought to compare the radiation dose, contrast volume, and procedure time between DARCA and conventional coronary angiography (CCA) techniques in a setting characterized by a prevalence of 100% suspected coronary artery disease. METHODS: An all-comer, prospective, randomized, open-label trial was conducted. Cine acquisition dose-area product (DAP), cumulative air kerma (AK), effective dose (E), fluoroscopic time, contrast volume, AK, cine acquisition DAP (CADAP), fluoroscopic DAP (F-DAP), and total DAP were compared between DARCA and CCA groups. RESULTS: We included 503 consecutive patients with suspected CAD. 252 were assigned to DARCA and 251 to CCA. Stable coronary artery disease was reported in 465 cases and non-ST elevation acute coronary syndrome in 38. Mean age: 61.88 ± 11.2 years, male gender 70.2%. DARCA arm patients showed lower total E dose (6.85 [4.55-10.83] vs. 7.91 [5.58-11.94] Sv; P = .0023), and cine E (3.00 [2.00-4.00] vs. 4.00 [3.00-5.00] Sv; P < .0001). Total DAP was also lower (40.3 [26.8-63.7] vs. 46.5 [32.8-70.2] Gycm2; P = .0023), as a consequence of a lower CADAP (16.3 [10.5-22.9] vs. 23.4 [17.4-32.0] Gycm2; P < .0001), with lower AK (367 [248-1497] vs. 497 [381-1827] mGy; P < .0001), with less contrast medium used (90 [60.0-106.0] vs. 100 [75.0-120.0] mL; P = .014). CONCLUSION: In a population with 100% suspected coronary artery disease, DARCA provides accurate information required in CAD, is safe, and results in a significant decrease in contrast material volume and radiation dose compared with CCA. The required extra projections did not neutralize the DARCA radiation dose and contrast volume reduction achievements.

[Simple mechanical reperfusion in acute myocardial infarction: determinants, prognostic implications and relation with thrombus histology]. / Reperfusión mecánica simple en el infarto agudo de miocardio. Determinantes, implicaciones en el pronóstico y relación con la histología del trombo.

Simple mechanical reperfusion (SMR) is defined as reperfusion achieved after wire insertion at the occluded infarct-related artery in primary angioplasty. The determinants and prognostic implications of SMR and its relationship with the histopathology of the rescued thrombus were evaluated in 601 patients with acute myocardial infarction showing ST elevation and pre-procedural total occlusion of the infarct-related artery (TIMI flow 0). Two groups were considered according to the presence of SMR, defined as the visualization of contrast material after crossing the occlusion with the guide wire. SMR was achieved in 303 patients (50.4%) and was found to be associated with less time to treatment (248 vs. 286 minutes; p = 0.001), less deteriorated initial left ventricular function and shock at admission (9.2 vs. 16.4%; p = 0.008), higher successful rate (94.7% vs. 78.5%; p < 0,0001) and of higher rate of thrombus rescue: 70/81 vs. 27/79 patients (p < 0.0001). The right coronary artery was the most frequent infarct-related artery. Histopathology of the retrieved thrombi was available for 160 patients treated with thrombus aspiration. SMR was associated with smaller thrombus, lower contents of leukocytes and erythrocytes, and higher thrombus content of inflammatory cells, cholesterol and collagen crystals from the atheromatous plaque. SMR is an independent predictor of procedure success and its relationship with the anatomy of the thrombus could redefine the indication of thrombus aspiration.

Reperfusión mecánica simple en el infarto agudo de miocardio: Determinantes, implicaciones en el pronóstico y relación con la histología del trombo / Simple mechanical reperfusion in acute myocardial infarction: determinants, prognostic implications and relation with thrombus histology

La reperfusión mecánica simple (RMS) es la lograda en la angioplastia primaria al atravesar la oclusión en la arteria responsable de infarto con la guía intracoronaria. Para evaluar los determinantes de la RMS, su implicación en el pronóstico y su relación con la histopatología del trombo rescatado, fueron analizados los casos de 601 pacientes con infarto agudo de miocardio con elevación del segmento ST y oclusión total de la arteria responsable de infarto (flujo TIMI 0). Se consideraron dos grupos según la presencia de RMS, definida por la visualización de contraste distal a la lesión luego de atravesarla con la guía intracoronaria. Se realizó el análisis histopatológico de los trombos en un subgrupo de 160 pacientes tratados con tromboaspiración. En 303 (50.4%) pacientes se obtuvo RMS. La RMS se asoció a menor ventana al tratamiento (248 vs. 286 minutos, p = 0.001), menor deterioro de la función sistólica ventricular izquierda inicial y shock al ingreso (9.2 vs.16.4%, p = 0.008), mayor tasa de éxito (94.7 vs. 78.5%, p < 0.0001) y de rescate de trombos (70/81 vs. 27/79 pacientes, p < 0.0001). La arteria responsable de infarto más frecuente fue la coronaria derecha. La RMS se asoció con menor tamaño del trombo, menor concentración de leucocitos y eritrocitos y mayor contenido de células inflamatorias, cristales de colesterol y colágeno provenientes de la placa. La RMS es un predictor independiente de éxito y su relación con la anatomía del trombo podría redefinir la indicación de la tromboaspiración.

Simple mechanical reperfusion (SMR) is defined as reperfusion achieved after wire insertion at the occluded infarct-related artery in primary angioplasty. The determinants and prognostic implications of SMR and its relationship with the histopathology of the rescued thrombus were evaluated in 601 patients with acute myocardial infarction showing ST elevation and pre-procedural total occlusion of the infarct-related artery (TIMI flow 0). Two groups were considered according to the presence of SMR, defined as the visualization of contrast material after crossing the occlusion with the guide wire. SMR was achieved in 303 patients (50.4%) and was found to be associated with less time to treatment (248 vs. 286 minutes; p = 0.001), less deteriorated initial left ventricular function and shock at admission (9.2 vs. 16.4%; p = 0.008), higher successful rate (94.7% vs. 78.5%; p < 0,0001) and of higher rate of thrombus rescue: 70/81 vs. 27/79 patients (p < 0.0001). The right coronary artery was the most frequent infarct-related artery. Histopathology of the retrieved thrombi was available for 160 patients treated with thrombus aspiration. SMR was associated with smaller thrombus, lower contents of leukocytes and erythrocytes, and higher thrombus content of inflammatory cells, cholesterol and collagen crystals from the atheromatous plaque. SMR is an independent predictor of procedure success and its relationship with the anatomy of the thrombus could redefine the indication of thrombus aspiration.

Initial Results and Long-Term Follow-up of Percutaneous Mitral Valvuloplasty in Patients with Pulmonary Hypertension.

BACKGROUND: Percutaneous balloon mitral valvuloplasty (PMV) is an attractive therapeutic approach in patients with mitral stenosis. The aim of this study was to assess the immediate and long-term clinical, echocardiographic and haemodynamic outcomes of PMV in patients with severe pulmonary hypertension (PAH). METHODS: Percutaneous balloon mitral valvuloplasty was performed in 157 consecutive patients; 60 patients (38.2%) had significant PAH defined as baseline pulmonary artery mean pressure (PAMP) ≥ 30mm Hg (Group 1) and 97 patients (61.8%) had PAMP ≤ 30mmHg (Group 2). Pulmonary artery systolic pressure (PASP), mortality, need for mitral valve replacement or new PMV, and valve restenosis were evaluated during follow-up. RESULTS: Mean age was 44.2 years and 88.5% (139 patients) were women. Primary success was achieved in 79.6% of the patients (125 patients) without differences between the groups. Mitral valve area increased from 0.90cm2 to 1.76cm2, PASP fell from 57mmHg to 35mmHg in Group 1 and from 38mmHg to 30mmHg in Group 2. Median PASP in Group 1 was 35, 32, 36, 38 and 34mmHg at 12, 24, 36, 48 and 60 months. There were no significant differences in mitral valve area, PASP and clinical status between the groups. CONCLUSION: Percutaneous balloon mitral valvuloplasty is a safe and effective technique for the treatment of patients with mitral stenosis and PAH. A significant decrease in pulmonary pressure was observed after valvuloplasty. Although there was a gradual decrease of MVA at long-term follow-up, most patients remained asymptomatic and PASP was stable.

Predictores clínicos de no-reflujo en la angioplastia coronaria por infarto agudo de miocardio / Clinical Predictors of No-Reflow in Percutaneous Coronary Intervention for Acute Myocardial Infarction

Introducción El fenómeno de no-reflujo en el contexto de la angioplastia por infarto agudo de miocardio (IAM) es un hecho relativamente frecuente y asociado con peor pronóstico. La detección de variables clínicas vinculadas a este fenómeno antes del inicio del procedimiento podría ayudar a la adopción de medidas preventivas y por consiguiente a mejorar los resultados. Objetivo Determinar predictores clínicos de no-reflujo en el contexto de la angioplastia por IAM con elevación del segmento ST antes del inicio del procedimiento. Material y métodos Se analizaron 742 pacientes con IAM de < 12 horas de evolución tratados con angioplastia primaria. Se excluyeron los pacientes con flujo epicárdico TIMI 0 posintervención y se consideró no-reflujo a la presencia de flujo TIMI 1-2 posangioplastia inmediato en ausencia de lesión residual. Se analizaron variables demográficas, factores de riesgo coronario, antecedentes y demora al tratamiento. Se realizó un análisis multivariado por regresión logística múltiple para determinar el valor pronóstico independiente de las variables relacionadas con el no-reflujo. Resultados Se incluyeron 675 pacientes. Presentaron fenómeno de no-reflujo 119 pacientes (17,6%). Los pacientes con no-reflujo tenían mayor edad (60,8 ± 12 vs. 57,0 ± 11 años; p = 0,0001) y menor frecuencia de tabaquismo activo (58,8% vs. 67,8%; p = 0,03) y de antecedentes familiares (22,7% vs. 37,8%; p = 0,0007), sin diferencias significativas en el resto de los factores de riesgo coronario y antecedentes cardiovasculares. Se observó también con mayor frecuencia localización anterior del IAM (58,8% vs. 43,7%; p = 0,002), signos clínicos de insuficiencia cardíaca al ingreso (17,6% vs. 10,1%; p = 0,01), así como mayor demora al tratamiento [240 (151-360) vs. 195 (120-302) minutos; p = 0,02]. El análisis multivariado determinó que los predictores independientes de no-reflujo fueron: edad > 60 años, localización anterior y demora al tratamiento > 3 horas. Conclusión La edad avanzada, la localización anterior y la demora al tratamiento resultaron predictores clínicos independientes de no-reflujo. La confirmación de estos hallazgos en estudios prospectivos permitiría implementar estrategias para prevenir su aparición y, eventualmente, mejorar los resultados clínicos a largo plazo.

Introduction The no-reflow phenomenon in the setting of primary coronary intervention for acute myocardial infarction (AMI) is relatively common and is associated with adverse outcomes. The detection of clinical variables associated with this phenomenon before the procedure might help to adopt preventive measures and thus improve the results. Objective The aim of this study was to identify clinical predictors of the no-reflow phenomenon in the setting of percutaneous coronary intervention for ST-segment elevation acute myocardial infarction, prior to the procedure. Methods A total of 742 patients with AMI < 12 hours since onset of symptoms treated with primary percutaneous coronary intervention were analyzed. Patients with epicardial TIMI grade 0 flow after the procedure were excluded. No-reflow was considered as the presence of TIMI grade 1-2 flow immediately after the procedure in the absence of residual stenosis. Demographic variables, coronary risk factors, family history and delay to reperfusion were analyzed. Multivariate logistic regression was used to determine the independent prognostic value of the variables associated with no-reflow. Results A total of 675 patients were included. The no-reflow phenomenon was present in 119 patients (17.6%). Patients with no-reflow were older (60.8 ± 12 vs. 57.0 ± 11 years; p = 0.0001) and had less prevalence of current smoking (58.8% vs. 67.8%, p = 0.03) and of previous history (22.7% vs. 37.8%, p = 0.0007), with no significant differences in the rest of coronary risk factors and history of cardiovascular disease. Anterior AMI (58.8% vs. 43.7%, p = 0.002), heart failure at admission (17.6% vs. 10.1%, p = 0.01) and delay to reperfusion (240 [151-360] vs. 195 [120-302] minutes, p=0.02) were more frequent in the no-reflow group. Multivariate analysis identified age > 60 years, anterior infarction and delay to reperfusion > 3 hours as independent predictors of no-reflow. Conclusion Advanced age, anterior infarction and delay to reperfusion were independent clinical predictors of no-reflow. The confirmation of these findings in prospective studies might allow the implementation of strategies to prevent this phenomenon and eventually improve the long-term clinical outcomes.

Predictores clínicos de no-reflujo en la angioplastia coronaria por infarto agudo de miocardio / Clinical Predictors of No-Reflow in Percutaneous Coronary Intervention for Acute Myocardial Infarction

Introducción El fenómeno de no-reflujo en el contexto de la angioplastia por infarto agudo de miocardio (IAM) es un hecho relativamente frecuente y asociado con peor pronóstico. La detección de variables clínicas vinculadas a este fenómeno antes del inicio del procedimiento podría ayudar a la adopción de medidas preventivas y por consiguiente a mejorar los resultados. Objetivo Determinar predictores clínicos de no-reflujo en el contexto de la angioplastia por IAM con elevación del segmento ST antes del inicio del procedimiento. Material y métodos Se analizaron 742 pacientes con IAM de < 12 horas de evolución tratados con angioplastia primaria. Se excluyeron los pacientes con flujo epicárdico TIMI 0 posintervención y se consideró no-reflujo a la presencia de flujo TIMI 1-2 posangioplastia inmediato en ausencia de lesión residual. Se analizaron variables demográficas, factores de riesgo coronario, antecedentes y demora al tratamiento. Se realizó un análisis multivariado por regresión logística múltiple para determinar el valor pronóstico independiente de las variables relacionadas con el no-reflujo. Resultados Se incluyeron 675 pacientes. Presentaron fenómeno de no-reflujo 119 pacientes (17,6%). Los pacientes con no-reflujo tenían mayor edad (60,8 ± 12 vs. 57,0 ± 11 años; p = 0,0001) y menor frecuencia de tabaquismo activo (58,8% vs. 67,8%; p = 0,03) y de antecedentes familiares (22,7% vs. 37,8%; p = 0,0007), sin diferencias significativas en el resto de los factores de riesgo coronario y antecedentes cardiovasculares. Se observó también con mayor frecuencia localización anterior del IAM (58,8% vs. 43,7%; p = 0,002), signos clínicos de insuficiencia cardíaca al ingreso (17,6% vs. 10,1%; p = 0,01), así como mayor demora al tratamiento [240 (151-360) vs. 195 (120-302) minutos; p = 0,02]. El análisis multivariado determinó que los predictores independientes de no-reflujo fueron: edad > 60 años, localización anterior y demora al tratamiento > 3 horas. Conclusión La edad avanzada, la localización anterior y la demora al tratamiento resultaron predictores clínicos independientes de no-reflujo. La confirmación de estos hallazgos en estudios prospectivos permitiría implementar estrategias para prevenir su aparición y, eventualmente, mejorar los resultados clínicos a largo plazo.(AU)

Introduction The no-reflow phenomenon in the setting of primary coronary intervention for acute myocardial infarction (AMI) is relatively common and is associated with adverse outcomes. The detection of clinical variables associated with this phenomenon before the procedure might help to adopt preventive measures and thus improve the results. Objective The aim of this study was to identify clinical predictors of the no-reflow phenomenon in the setting of percutaneous coronary intervention for ST-segment elevation acute myocardial infarction, prior to the procedure. Methods A total of 742 patients with AMI < 12 hours since onset of symptoms treated with primary percutaneous coronary intervention were analyzed. Patients with epicardial TIMI grade 0 flow after the procedure were excluded. No-reflow was considered as the presence of TIMI grade 1-2 flow immediately after the procedure in the absence of residual stenosis. Demographic variables, coronary risk factors, family history and delay to reperfusion were analyzed. Multivariate logistic regression was used to determine the independent prognostic value of the variables associated with no-reflow. Results A total of 675 patients were included. The no-reflow phenomenon was present in 119 patients (17.6%). Patients with no-reflow were older (60.8 ± 12 vs. 57.0 ± 11 years; p = 0.0001) and had less prevalence of current smoking (58.8% vs. 67.8%, p = 0.03) and of previous history (22.7% vs. 37.8%, p = 0.0007), with no significant differences in the rest of coronary risk factors and history of cardiovascular disease. Anterior AMI (58.8% vs. 43.7%, p = 0.002), heart failure at admission (17.6% vs. 10.1%, p = 0.01) and delay to reperfusion (240 [151-360] vs. 195 [120-302] minutes, p=0.02) were more frequent in the no-reflow group. Multivariate analysis identified age > 60 years, anterior infarction and delay to reperfusion > 3 hours as independent predictors of no-reflow. Conclusion Advanced age, anterior infarction and delay to reperfusion were independent clinical predictors of no-reflow. The confirmation of these findings in prospective studies might allow the implementation of strategies to prevent this phenomenon and eventually improve the long-term clinical outcomes.(AU)

Resultados inmediatos y seguimiento a largo plazo de la valvuloplastia mitral percutánea / Immediate Outcomes and Long-Term Follow-Up of Percutaneous Mitral Valvuloplasty

Introducción El tratamiento de la estenosis mitral ha cambiado en las últimas décadas. Se ha demostrado que, frente al tratamiento quirúrgico, la valvuloplastia mitral percutánea (VMP) presenta resultados hemodinámicos comparables y una evolución similar. Objetivo Evaluar la eficacia y la evolución clínica y ecocardiográfica inmediata y a largo plazo de la VMP. Material y métodos Se incluyeron 132 pacientes que habían sido sometidos a VMP, con una mediana de seguimiento de 48 meses. Se consideró éxito primario cuando se obtuvo un área pos-VMP ≥ 1,5 cm². En el seguimiento se evaluaron: muerte, necesidad de reemplazo valvular mitral o de nueva VMP y reestenosis valvular. Resultados La media de edad fue de 44,6 años; el 88,5% de los pacientes (n = 115) eran de sexo femenino. La mediana del área valvular mitral pre-VMP era de 0,90 cm² (IIC 25-75: 0,81-1,00), la presión sistólica de la arteria pulmonar era de 44 mm Hg (IIC 25-75: 35-52) y el puntaje ecocardiográfico, de 7 (IIC 25-75: 6-9). Se obtuvo éxito primario en 104 pacientes (78,8%). En el seguimiento a 4 años, el 86,5% de los pacientes (n = 109) se encontraban asintomáticos. Se registraron tres muertes intrahospitalarias (2,2%) y tres en el seguimiento (2,2%). Se realizó una nueva VMP en 10 pacientes y reemplazo valvular mitral en cuatro. Las variables asociadas con reestenosis en el seguimiento fueron el puntaje ecocardiográfico > 8 (p = 0,04) y el área valvular mitral pos-VMP < 1,8 cm² (p = 0,02). Luego del análisis multivariado, el área valvular mitral pos-VMP < 1,8 cm² fue el único predictor de reestenosis (OR: 2,6; IC 95%: 1,08-6,25). Conclusiones La VMP es segura y eficaz, eficacia que se mantiene a largo plazo. Los mejores resultados inmediatos se obtienen en pacientes con puntaje ecocardiográfico bajo y en ritmo sinusal, mientras que aquellos con un área valvular mitral mayor pos-VMP son los que presentan menor reestenosis en el seguimiento.

Background The treatment of mitral valve stenosis has changed over the last decades. The hemodynamic results and the outcome of percutaneous mitral valvuloplasty (PMV) have proved to be comparable to those of surgical treatment. Objective To evaluate the efficacy and the immediate and long-term clinical and echocardiographic outcome of PMV. Methods A total of 132 patients undergoing PMV were included, with a median follow-up of 48 months. The primary success was defined as a mitral valve area of ≥ 1.5 cm² following PMV. Mortality, need for mitral valve replacement or new PMV and mitral valve restenosis were evaluated during follow-up. Results Mean age was 44.6 years; 88.5% of patients (n=115) were women. Median mitral valve area before PMV was 0.90 cm² (IQR 25-75: 0.81-1.00), systolic pulmonary artery pressure was 44 mm Hg (IQR 25-75: 35-52) and the echocardiographic score was 7 (IQR 25-75: 6-9). Primary success was achieved in 104 patients (78.8%). After four years of follow-up, 86.5% of patients (n=109) were free of symptoms. Three patients (2.2%) died during hospitalization and three (2.2%) during follow-up. A new PMV was performed in 10 patients and four patients underwent mitral valve replacement. During follow-up, an echocardiographic score of >8 (p=0.04) and a mitral valve area following PMV of 2 (p=0.02) were the variables associated with restenosis. After performing multivariate analysis, the only predictor associated with restenosis following PMV was a mitral valve area 2 (OR: 2.6; 95% CI: 1.08-6.25). Conclusions Percutaneous mitral valvuloplasty is a safe and efficient method with long-term efficacy. The best outcomes are achieved in patients with low echocardiographic score and who are in sinus rhythm, and those with greater mitral valve area following PMV have lower restenosis during follow-up.

Resultados inmediatos y seguimiento a largo plazo de la valvuloplastia mitral percutánea / Immediate Outcomes and Long-Term Follow-Up of Percutaneous Mitral Valvuloplasty

Introducción El tratamiento de la estenosis mitral ha cambiado en las últimas décadas. Se ha demostrado que, frente al tratamiento quirúrgico, la valvuloplastia mitral percutánea (VMP) presenta resultados hemodinámicos comparables y una evolución similar. Objetivo Evaluar la eficacia y la evolución clínica y ecocardiográfica inmediata y a largo plazo de la VMP. Material y métodos Se incluyeron 132 pacientes que habían sido sometidos a VMP, con una mediana de seguimiento de 48 meses. Se consideró éxito primario cuando se obtuvo un área pos-VMP ≥ 1,5 cm². En el seguimiento se evaluaron: muerte, necesidad de reemplazo valvular mitral o de nueva VMP y reestenosis valvular. Resultados La media de edad fue de 44,6 años; el 88,5% de los pacientes (n = 115) eran de sexo femenino. La mediana del área valvular mitral pre-VMP era de 0,90 cm² (IIC 25-75: 0,81-1,00), la presión sistólica de la arteria pulmonar era de 44 mm Hg (IIC 25-75: 35-52) y el puntaje ecocardiográfico, de 7 (IIC 25-75: 6-9). Se obtuvo éxito primario en 104 pacientes (78,8%). En el seguimiento a 4 años, el 86,5% de los pacientes (n = 109) se encontraban asintomáticos. Se registraron tres muertes intrahospitalarias (2,2%) y tres en el seguimiento (2,2%). Se realizó una nueva VMP en 10 pacientes y reemplazo valvular mitral en cuatro. Las variables asociadas con reestenosis en el seguimiento fueron el puntaje ecocardiográfico > 8 (p = 0,04) y el área valvular mitral pos-VMP < 1,8 cm² (p = 0,02). Luego del análisis multivariado, el área valvular mitral pos-VMP < 1,8 cm² fue el único predictor de reestenosis (OR: 2,6; IC 95%: 1,08-6,25). Conclusiones La VMP es segura y eficaz, eficacia que se mantiene a largo plazo. Los mejores resultados inmediatos se obtienen en pacientes con puntaje ecocardiográfico bajo y en ritmo sinusal, mientras que aquellos con un área valvular mitral mayor pos-VMP son los que presentan menor reestenosis en el seguimiento.(AU)

Background The treatment of mitral valve stenosis has changed over the last decades. The hemodynamic results and the outcome of percutaneous mitral valvuloplasty (PMV) have proved to be comparable to those of surgical treatment. Objective To evaluate the efficacy and the immediate and long-term clinical and echocardiographic outcome of PMV. Methods A total of 132 patients undergoing PMV were included, with a median follow-up of 48 months. The primary success was defined as a mitral valve area of ≥ 1.5 cm² following PMV. Mortality, need for mitral valve replacement or new PMV and mitral valve restenosis were evaluated during follow-up. Results Mean age was 44.6 years; 88.5% of patients (n=115) were women. Median mitral valve area before PMV was 0.90 cm² (IQR 25-75: 0.81-1.00), systolic pulmonary artery pressure was 44 mm Hg (IQR 25-75: 35-52) and the echocardiographic score was 7 (IQR 25-75: 6-9). Primary success was achieved in 104 patients (78.8%). After four years of follow-up, 86.5% of patients (n=109) were free of symptoms. Three patients (2.2%) died during hospitalization and three (2.2%) during follow-up. A new PMV was performed in 10 patients and four patients underwent mitral valve replacement. During follow-up, an echocardiographic score of >8 (p=0.04) and a mitral valve area following PMV of 2 (p=0.02) were the variables associated with restenosis. After performing multivariate analysis, the only predictor associated with restenosis following PMV was a mitral valve area 2 (OR: 2.6; 95% CI: 1.08-6.25). Conclusions Percutaneous mitral valvuloplasty is a safe and efficient method with long-term efficacy. The best outcomes are achieved in patients with low echocardiographic score and who are in sinus rhythm, and those with greater mitral valve area following PMV have lower restenosis during follow-up.(AU)